Vitruvian Shield Holding SA incorporated in Épalinges, Switzerland.
About
Building the clinical evidence platform
From a biomedical engineering vision to an AI-native clinical evidence platform, built in Switzerland since 2016.
Our Story
Vitruvian Shield was founded in 2016 with a clear conviction: clinical trials shouldn't require patients to organize their lives around clinic visits, and researchers shouldn't drown in fragmented technology stacks just to collect quality data.
What began as a remote patient monitoring research project evolved into a platform that brings wearable and connected-device data and patient-reported outcomes into one traceable dataset, next to the EDC the sponsor already uses.
Today, Vitruvian Shield builds an AI-native clinical evidence platform for hybrid trials and post-market surveillance. The evidence layer comes first: continuous home-collected data with provenance, identity assurance, a signal-confidence score and an audit trail, designed to ALCOA++ data-integrity principles and GDPR requirements and designed for ICH E6(R3) and FDA 21 CFR Part 11. Studies are in preparation with Portuguese university hospitals and test beds, and the platform has been deployed and tested with a neurology team at CHUV, Lausanne.
Recognition
Industry awards and recognition received by Vitruvian Shield and its leadership.
European CEO of the Year 2024-2025
Awarded to Paulo Martins for leadership in AI-driven decentralized clinical trial infrastructure.
Portuguese National Innovation Award 2024
For contribution to the national innovation ecosystem.
APDC Health Award, First Place 2025
Awarded by the Portuguese Association for the Development of Communications.
World Summit Awards Portugal 2024 Winner
In the Health and Well-Being category.
Group entities
Vitruvian Shield operates through legal entities across Europe, the South Caucasus, and the Middle East.
- LausanneHeadquarters · Vitruvian Shield Holding SA & Vitruvian Shield SA
- AveiroPortuguese subsidiary · Vitruvian Shield PT LDA
- YerevanEngineering centre · Vitruvian Shield AM
- DubaiUAE market entry · Vitruvian Shield FZCO (DMCC)
Company History
Milestones along the path from a biomedical engineering vision to an AI-native clinical evidence platform.
Scroll to advance timeline
Platform inception. Remote patient monitoring research evolves into the foundation for a full DCT infrastructure layer.
Portuguese entity established; operations ramp at PCI Creative Science Park, Aveiro.
Armenia engineering centre opened in Yerevan; core platform services scale.
Platform deployed and tested with a neurology team at CHUV, fixes delivered April 2026; positioning as an AI-native clinical evidence platform; Portuguese test-bed and academic relationships established; the company's first commercial offer, built on ICH E6(R3) Annex 2.
Global Presence
Headquartered in Switzerland. Operating across Europe, the South Caucasus, and the Middle East.
CH
Switzerland
Vitruvian Shield Holding SA (CHE-380.090.655) and Vitruvian Shield SA (CHE-390.132.812). Headquartered at Biopole Life Sciences Campus, Rue de la Corniche 3b, 1066 Epalinges. Platform architecture, regulatory strategy, and business development.
PT
Portugal
Vitruvian Shield PT LDA (NIPC 517508729). Based at PCI Creative Science Park Aveiro Region, Ilhavo. Clinical operations, software development, and clinical trial execution.
AM
Armenia
Vitruvian Shield AM (Reg. 264.110.1489516). Operating from Hakob Hakobyan 3, Mergelyan Institute, Yerevan. Engineering hub for AI/ML, data engineering, and platform infrastructure.
AE
UAE
Vitruvian Shield FZCO (Licence DMCC-945790). Registered at DMCC, Dubai. Market expansion and partnerships with Gulf healthcare systems.
Studies and partner work
Studies in preparation and partner work on the Vitruvian Shield platform. No study result is claimed.
Oncology electronic survey study, ULS Coimbra
In preparation. An observational oncology eSurvey study with clinical investigators at ULS Coimbra, prepared through the TEF-Health facility operated by Instituto Pedro Nunes, using EORTC QLQ-C30 and PRO-CTCAE.
PT-EPI-DCT-002, decentralised seizure monitoring in adult epilepsy, ULS Santa Maria
In preparation. A single-site decentralised study protocol, version 2.0, prepared with ULS Santa Maria in Lisbon under the TB4Health test-bed programme; ethics submission targeted before the end of 2026.
Multiple sclerosis investigator-initiated study, ULS Coimbra
Letter of interest. Coimbra investigators signed a non-binding letter of interest on 2 September 2026 for use of the platform in a future multiple sclerosis study.
CHUV, Lausanne
Deployed and tested. The platform was deployed and tested with a neurology team at CHUV; fixes were delivered in April 2026 and re-engagement is planned.
Leadership
The named executives accountable for platform direction, regulatory posture, engineering, and quality across our four legal entities.
Full team, including engineering, clinical, and strategic advisors, listed below.
Non-Dilutive Capital & Recognition
A diversified, non-dilutive funding base signals capital efficiency and institutional recognition.
Innosuisse · Aide Suisse à la Montagne · ANI
Research Grants
Innosuisse (Switzerland), Aide Suisse à la Montagne (Switzerland), and ANI (Portugal). Non-dilutive research and innovation funding secured to date.
Microsoft Azure and Google Cloud
Cloud Sponsorships
Cloud startup programme credits awarded by Microsoft Azure and Google Cloud.
2025-2026
Selo de Idoneidade Científica
Portuguese scientific validity certification, renewed for the 2025-2026 cycle.
Additional financing disclosures are shared privately with qualified investors on request.
Our People
A 25-person team across Switzerland, Portugal, Armenia, and the UAE. Selected members shown below.
Executive Leadership
Clinical and Strategic Advisors
Our Values
The principles that guide every decision we make.
Regulatory Integrity
Compliance isn't a feature, it's the foundation. Every line of code is written with regulatory inspection readiness as a first-class requirement, not an afterthought.
Patient Centricity
Technology should reduce patient burden, not add to it. We design every workflow around the question: does this make the patient's experience better?
Scientific Rigor
Clinical decisions must be grounded in validated data. We build tools that generate evidence you can trust, no shortcuts, no compromises on data integrity.
Speed of Execution
The urgency of clinical research demands velocity. We move fast, ship continuously, and iterate relentlessly, without ever sacrificing quality or compliance.